Толперизон-OBL

Quick links

Choose a section

Quick links to important sections

Advertisements

Толперизон-OBL

Advertisements
Advertisements

Overview of Толперизон-OBL

What is Tolperisone-OBL?

Property Description
Active ingredient Tolperisone hydrochloride
Form Tablet (Oral)
Pharmacological class Centrally Acting Muscle Relaxant
Common use Treating increased muscle tone (spasticity)
Availability Prescription Only

Tolperisone-OBL is the brand name of a prescription medication that contains the active ingredient tolperisone hydrochloride. This drug is formally classified as a centrally acting muscle relaxant, a category of medicines used to relieve muscle stiffness and tension by influencing nerve signals within the central nervous system.

The medication's primary indication is the management of pathologically increased muscle tone, clinically known as spasticity, which can result from neurological conditions such as stroke or from certain musculoskeletal disorders. The active substance, tolperisone, is an established drug approved in numerous countries for this therapeutic purpose.

Tolperisone is chemically categorized as a piperidine derivative. A significant distinguishing feature of tolperisone is its profile compared to older muscle relaxants. It is generally associated with a lower risk of causing sedation or drowsiness. This reduced potential for mental impairment makes it an option for patients who need to maintain focus and alertness throughout the day.

Tolperisone-OBL is supplied exclusively as an oral tablet and requires a valid prescription from a healthcare provider for dispensing.

Advertisements

What side effects are possible with Толперизон-OBL?

The safety profile of Tolperisone-OBL (tolperisone hydrochloride) is defined by classifications of adverse reactions as documented in official government regulatory prescribing information.

Frequency-Classified Adverse Reactions

The most significant safety consideration is the risk of hypersensitivity reactions, which can range from uncommon skin effects to rare and potentially life-threatening severe systemic reactions, including anaphylactic shock. Regulatory documents note that these severe allergic events are observed most frequently during the initial few months of treatment.

The majority of non-serious adverse reactions are classified as uncommon (affecting 1 to 10 users in 1,000) and are primarily associated with two System-Organ Classes:

  • Nervous System Disorders: May include headache, dizziness, and somnolence (drowsiness).
  • Gastrointestinal Disorders: May manifest as abdominal pain, nausea, and dyspepsia.

Rare adverse reactions (affecting 1 to 10 users in 10,000) may involve cardiovascular, dermatological, and hepatic systems, such as palpitations, rash, or changes in liver enzyme levels.

Population-Specific Safety Constraints

The medicine's regulatory safety documentation specifies conditions where use is limited or prohibited:

  • Contraindications: Tolperisone-OBL is formally contraindicated in individuals with myasthenia gravis and in those with known hypersensitivity to tolperisone or the related compound eperisone.
  • Severe Impairment: Use is not recommended in patients with severe hepatic impairment or severe renal impairment.
  • Pediatric Use: Safety and efficacy in children under 18 years of age have not been established in official labeling.
Advertisements

Overdose and Emergency Response

The official regulatory profile for Толперизон-OBL overdose describes a range of clinical signs that necessitate immediate attention. Documented overdose presentations may include central nervous system effects such as somnolence and vertigo, along with motor and cardiovascular signs like bradykinesia and tachycardia. Gastrointestinal symptoms, including nausea, vomiting, and epigastric pain, are also listed in regulatory texts.

Severe Outcomes and Emergency Action

In severe cases, the acute overdose is associated with the risk of life-threatening outcomes. These severe manifestations documented in regulatory reports include seizure, coma, apnoea (cessation of breathing), and respiratory depression. Ingestion of high doses in children has also been associated with severe, dose-related central nervous system symptoms.

Due to the risk of severe complications, official regulatory documents mandate that the patient contact a doctor or pharmacist or an emergency department immediately if an overdose is suspected. Management of the overdose is strictly symptomatic because official labeling confirms that no special antidote is known for tolperisone. This regulatory stance on management underscores the need for urgent clinical intervention and supportive care.

Advertisements

Therapeutic Uses of Толперизон-OBL

What Толперизон-OBL Treats: Main Uses and Benefits

Толперизон-OBL is commonly used across conditions presenting with acute episodes and symptoms related to increased neurological or muscular activity. It is applied in contexts where additional symptomatic support is needed, and may assist with managing discomfort associated with these issues. Its benefits are recognized in the symptomatic management of conditions associated with central nervous system disorders.


Supportive Symptom Relief

Толперизон-OBL is generally used in conditions characterized by periods of heightened symptoms and acute or disruptive episodes. It is applied across domains where short-term symptom management is appropriate, helping to address symptom clusters that may become intense or disruptive. The medication plays a role in managing symptoms that create noticeable physiological strain, which contributes to improved day-to-day comfort during symptomatic periods. This approach is aligned with the goal of managing the patient experience, providing support that helps ease the overall symptom burden. It is relevant in contexts marked by increased discomfort or tension, and often used during phases when symptoms become more noticeable, offering relief that supports general well-being.

Quick Fact: Relief for Heightened Physiological Strain

Regulatory References

  1. European Medicines Agency therapeutic overview
Advertisements

Eligibility and Restrictions for Use

The eligibility profile for Толперизон-OBL (Tolperisone) is strictly defined by regulatory documents, outlining populations for whom use is allowed and those for whom it is absolutely restricted or contraindicated.

Eligibility Group Regulatory Status
Contraindicated Populations The medicine must not be used by individuals with Myasthenia gravis, patients with a known hypersensitivity to tolperisone or its components, or nursing mothers (lactation).
Established Use Primarily established and permitted for adult patients (above 18 years of age).

Age and Organ Function Restrictions

Age-Related Eligibility: Use is established in adults, but regulatory guidance, such as from the EMA, specifically restricts the oral indication to adults with post-stroke spasticity. Safety and efficacy data for pediatric populations (children) are limited, resulting in the status of 'not established' or restricted use in many regions. Older adults may require special consideration or a reduced dosage.

Organ Function and Reproductive Status: Patients with severe hepatic impairment or severe renal impairment are not recommended to use the medicine due to altered clearance and potential accumulation. For those with moderate impairment, use is conditional, requiring close monitoring and individual dose adjustment. Use during pregnancy is also generally not recommended unless the prescribing authority deems the potential benefit to outweigh the risk, owing to a lack of sufficient controlled safety data.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes specific pharmacokinetic and pharmacodynamic interactions for Tolperisone.

Tolperisone is documented as a cytochrome P450 2D6 (CYP2D6) inhibitor. This mechanism means that co-administration of Tolperisone with other medicinal products that are CYP2D6 substrates (products metabolized predominantly by CYP2D6) may lead to increased plasma concentrations of the co-administered drug. Thioridazine is one such product explicitly noted in regulatory documents as a CYP2D6 substrate that requires attention when combined with Tolperisone.

Co-administration with tolfenamic acid presents a reverse interaction, where tolfenamic acid has been shown to increase the plasma concentration of Tolperisone. This necessitates consideration for a potential dose reduction of Tolperisone when these two medicines are taken together.

Interacting Product Category Official Regulatory Constraint/Action
CYP2D6 Substrates (e.g., Thioridazine) Potential for increased plasma concentration of the co-administered drug; use with caution and monitoring.
Tolfenamic Acid Consider dose reduction of Tolperisone due to increased Tolperisone plasma concentration.
Other Centrally Acting Muscle Relaxants Consider dose reduction of the co-administered muscle relaxant.

These constraints define the interaction structure for the product, highlighting the need for careful review and potential adjustment of dosing for co-administered medicines that fall within these categories.

Advertisements

Mechanism of Action

How Толперизон-OBL Works


Modulation of Neuronal Excitability

Толперизон-OBL functions as a membrane-stabilizing agent by directly blocking voltage-gated sodium and calcium channels on neuronal membranes, primarily within the central nervous system. This direct interaction stabilizes the neuronal membrane potential, resulting in a reduction in nerve impulse generation and transmission frequency along motor and afferent pathways.


Central Nervous System Reflex Inhibition

The drug engages mechanisms that depress spinal reflex pathways, particularly the polysynaptic reflexes. By targeting signal sequences in the brainstem and spinal cord, it modifies early molecular steps that govern motor output regulation and affects the excitability of motor pathways.


Presynaptic Neurotransmitter Control

Its dual ion channel blockade also contributes to the inhibition of presynaptic release of excitatory neurotransmitters from primary afferent endings. This modification of the signaling cascade modulates the intensity of downstream signaling and affects efferent motor control, influencing the basal tone of associated musculature.

Advertisements

Dosage and Administration Information

How to use Толперизон-OBL — Official Administration Guidelines

Tolperisone-OBL is administered based on a standardized protocol, which focuses on the correct route, dosing schedule, and intake conditions.


Administration Scope

Field Standardized Administration Instructions
Route of administration Oral administration is the required method, delivered via the film-coated tablet form. The oral route is the designated method for this formulation.
Dosing schedule The total daily dose typically ranges from 150 mg to 450 mg. The regimen is often initiated with 50 mg taken three times daily, totaling 150 mg per day. Dosing is individually adjusted within this range.
Timing in relation to meals The tablets must be taken after meals (postprandially) with a glass of water. This is a requirement to ensure adequate absorption and bioavailability of the active substance.
Age-group rules Paediatric Population: Safety and efficacy have not been established. Hepatic/Renal Impairment: Use is not recommended in severe impairment; moderate impairment requires individualized dose titration.
Missed-dose rule If a dose is forgotten, the instruction is to skip the missed dose entirely and continue with the regular schedule. A double dose should never be taken to compensate for a missed amount.

Connection to the Official Use Protocol

The administration protocol incorporates the consistent oral route and a fixed daily frequency of three divided doses (TID) to maintain steady systemic exposure. This framework dictates a standardized, dose-titrated regimen where the precise timing of intake after food is a procedural requirement. The tablets must be swallowed whole to ensure proper delivery.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Толперизон-OBL

Evidence for Use in Spasticity Following Cerebral Stroke

This section summarizes the structure of the clinical evaluation for tolperisone, focusing on research evaluating the medicine in the context of pathologically increased muscle tone (spasticity) that results from damage to the central nervous system following a stroke. The evidence base includes Randomized Controlled Trials (RCTs) and studies that compared the medicine against an inactive treatment, known as a placebo, which is the highest standard of clinical research.

Studies monitored changes in muscle tone using objective clinical rating scales, and assessments of functional abilities such as mobility and overall clinical condition.

Regulatory reviews have cited findings from a key RCT that described patterns observed in the studies regarding changes in the measured objective spasticity scores when tolperisone was assessed against a placebo. Research provides context, but long-term effects are not fully established by the highest-quality evidence, as these trials typically monitored patients for periods of up to 12 weeks.


Evidence for Use in Painful Reflex Muscle Spasm

This part outlines the research base for the short-term use of the medicine in acute musculoskeletal conditions associated with episodes of heightened symptom activity. The core research consists of short-term Randomized Controlled Trials (RCTs), often placebo-controlled, along with studies that included active comparator groups (other centrally acting muscle relaxants).

These studies primarily included adults experiencing acute, painful muscle spasms of the back of recent onset. Research examined outcomes related to physical discomfort, such as patient-reported outcomes describing perceived discomfort and objective changes in muscle function and range of motion over defined time intervals. Follow-up durations were limited in these primary RCTs, meaning research provides limited insight into long-term changes or the effects of the medicine beyond the acute treatment phase.


What is Still Uncertain About the Research for Толперизон-OBL

This concluding section synthesizes the main evidence gaps noted by scientific reviewers. A core limitation is that the most methodologically strong evidence, particularly for post-stroke spasticity, is mainly based on a single pivotal study, and the evidence quality varies across studies for the other indications. Follow-up durations were limited in the acute pain studies, meaning research exploring short-term symptom changes is better characterized than long-term effects. Evidence also highlights what is still uncertain regarding outcomes in special populations or chronic conditions.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Толперизон-OBL (FAQ)

Q: Is Tolperisone-OBL the same as Mydocalm?

Regulatory documents confirm that the active substance in both Tolperisone-OBL and Mydocalm is tolperisone hydrochloride. This indicates that they share the same active ingredient, which is classified as a centrally acting muscle relaxant. Any specific formulations or inactive ingredients may vary between different product names.

Q: Can I take Tolperisone-OBL with alcohol?

Official information indicates that tolperisone does not interact with alcohol and is not documented to enhance alcohol’s sedative effects. However, caution with alcohol use is generally advised, as alcohol consumption may still impact the underlying condition being treated.

Q: Is Tolperisone-OBL allowed for use in children?

Official regulatory guidance indicates that safety and effectiveness for tolperisone tablets have not been established for children and adolescents under 18 years of age through controlled clinical studies.

Q: Can I take Tolperisone-OBL during pregnancy?

The use of this medicine during pregnancy is not recommended, particularly in the first three months, due to a lack of sufficient controlled safety data in humans. Official guidelines state that use is generally considered after a risk-benefit assessment by a healthcare provider.

Q: Does Tolperisone-OBL affect blood pressure?

Official documents list hypotension (lowered blood pressure) as a rare undesirable reaction. Other rare cardiovascular effects, such as bradycardia (slowed heart rate), have also been described in the official product information.

Q: Does taking Tolperisone-OBL affect the ability to drive?

Official instructions warn that the medicine may cause undesirable reactions such as dizziness and somnolence (drowsiness). Individuals who experience these reactions are advised to proceed with caution regarding operating machinery or driving.

Q: Can I take Tolperisone-OBL if I have stomach problems?

Uncommon side effects include gastrointestinal disorders such as nausea, vomiting, and indigestion. Official documents do not list common stomach problems as a direct contraindication, but regulatory guidance requires taking the tablet after meals to help ensure adequate absorption.

Q: Are there restrictions for taking Tolperisone-OBL for people with kidney failure?

Use of the medicine is not recommended for patients who have severe renal impairment (severe kidney problems). In cases of moderate kidney impairment, official guidelines require careful monitoring and individualized dose adjustment.

Q: What data is available on the effect of Tolperisone-OBL on the heart?

The list of rare adverse reactions in regulatory documentation includes effects on the cardiovascular system such as palpitations (fast or fluttering heartbeat), bradycardia (slow heart rate), and hypotension (low blood pressure).

Q: Why do doctors often prescribe Tolperisone-OBL for back pain?

The official indication for the medicine includes the relief of painful muscle spasm associated with acute diseases of the musculoskeletal system in adults. Since muscle spasm is a frequent component of acute back pain, this falls within the drug’s regulatory scope of use.

Q: Can Tolperisone-OBL cause drowsiness or weakness?

Official safety data lists somnolence (drowsiness) as an uncommon side effect. Additionally, the official documents describe muscle weakness (asthenia) as another non-frequent undesirable reaction that may occur.

Q: Does Tolperisone-OBL cause addiction or dependence?

Official pharmacological data and clinical profiles for tolperisone do not describe the medicine as causing physical dependence or addiction, distinguishing it from certain other classes of muscle relaxants.

Q: What to do in case of an overdose of Tolperisone-OBL?

Official overdose information states that symptoms may include drowsiness, dizziness, or agitation, and in severe cases, convulsions or difficulty breathing. If an overdose is suspected, official instructions state that immediate medical attention should be sought. Official documents also note there is no specific antidote, and treatment is supportive.

Q: Is Tolperisone-OBL a hormonal drug or not?

Tolperisone-OBL is not a hormonal drug. It is formally classified as a centrally acting muscle relaxant, meaning it works by affecting nerve signals within the central nervous system to relieve muscle stiffness.

Q: Can I take Tolperisone-OBL if I'm on birth control pills?

Tolperisone is noted in official documents as an inhibitor of the enzyme CYP2D6. This mechanism can potentially increase the concentration of other drugs metabolized by CYP2D6. Given this, it is important that a healthcare provider reviews all concomitant medications.

Q: Does Tolperisone-OBL affect mood or emotional state?

Uncommon and rare adverse effects on the nervous system are listed, including headache, dizziness, and, rarely, confusion. While these effects may indirectly impact emotional state, official sources do not specifically describe a direct effect on mood.

Q: Why does dry mouth sometimes occur when taking Tolperisone-OBL?

Official safety documents list dry mouth (xerostomia) as an uncommon side effect. However, official sources generally do not provide specific mechanistic explanations for non-serious side effects to patients.

Q: How long does the effect last after stopping Tolperisone-OBL?

Pharmacokinetic data indicates that tolperisone has a short half-life (around 1.5–2.5 hours), meaning the majority of the substance is quickly eliminated from the body after the last dose. The residual clinical effect is variable and not detailed in official prescribing information.

Q: Can Tolperisone-OBL be used for sports injuries?

The official indication is to relieve painful muscle spasm in acute musculoskeletal conditions. Although sports injuries often involve such spasms, official documents do not list sports injuries as a specific, standalone indication for the medicine.

Q: Is it true that Tolperisone-OBL is often prescribed in combination with NSAIDs?

Official interaction data notes that certain NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), such as tolfenamic acid, can increase the concentration of tolperisone in the blood, potentially requiring a dose adjustment of tolperisone. However, the common practice of co-prescription is not addressed in the regulatory product information.

Q: Can Tolperisone-OBL interact with herbal supplements?

Tolperisone is noted in official documents as a CYP2D6 enzyme inhibitor. Therefore, any herbal supplements that are metabolized by or influence this enzyme could potentially interact with tolperisone. Specific herbal products are not individually named in the regulatory warnings.

Q: What side effects of Tolperisone-OBL are rare?

Rare undesirable reactions (those affecting 1 to 10 out of every 10,000 users) listed in regulatory documents include severe reactions like anaphylaxis (a serious allergic reaction), changes in heart rate (tachycardia), tremor, confusion, skin dryness, and elevation of liver enzyme levels.

Q: What is the difference between Tolperisone-OBL tablets and injections?

The official documentation confirms that the oral form (tablets) is specifically indicated for the treatment of spasticity in adults following a stroke. The intravenous or intramuscular injection forms (if available) may have different indications or patient populations than the Tolperisone-OBL tablets.

Advertisements

How should Толперизон-OBL be stored and disposed of?

How to Store and Dispose of Толперизон-OBL?

This section outlines the official, regulatory requirements for storing and discarding Толперизон-OBL tablets, ensuring product integrity and safety.

Official Storage Requirements

The medication must be stored in its original container to maintain stability and protection. The official storage temperature is not to exceed 30 C.

Condition Requirement
Temperature Store below 30 C (Cool Place)
Protection Keep in a dry place and protect from light
Safety Mandatory: Keep out of the sight and reach of children

Disposal Instructions

Unused or expired Толперизон-OBL must be disposed of according to local pharmaceutical waste regulations. The regulatory guidance explicitly states that the product should not be flushed down the toilet or allowed to enter drains, preventing environmental contamination. Disposal via an authorized drug take-back program or safe household methods is recommended.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Толперизон-OBL found in:

A-Z Index: